Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.49 |
| ▸ | MMP7 | P09237 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 3/20 | 0.49 |
| ▸ | MMP12 | P39900 | 3/20 | 0.49 |
| ▸ | MMP13 | P45452 | 3/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15177296 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2GLANPC1GAAKEAP1 | |
| SCHEMBL8192690 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2GLANPC1GAAKEAP1 | |
| SCHEMBL12390979 | 0.96 | SMN1; SMN2 (0.64) | SMN1; SMN2GLANPC1GAAKEAP1 | |
| SCHEMBL18410344 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2GLANPC1GAAKEAP1 | |
| SCHEMBL12391143 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2GLANPC1GAACNR2 | |
| SCHEMBL8626916 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2GLANPC1GAACNR2 | |
| SCHEMBL14701542 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2GLANPC1GAAKEAP1 | |
| SCHEMBL11711049 | 0.91 | SMN1; SMN2 (0.56) | SMN1; SMN2GLANPC1GAAKEAP1 | |
| SCHEMBL2805282 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2GLANPC1GAAKEAP1 | |
| SCHEMBL23297778 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2GLANPC1GAAKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114106669-B | Curing agent based on N-hydroxyethyl benzene sulfonamide compound and preparation method and application thereof | 镇江牛盾新材料科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-114106669-A | Curing agent based on N-hydroxyethyl benzene sulfonamide compound and preparation method and application thereof | 镇江牛盾新材料科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-8859694-B2 | Cure accelerators | HEXCEL COMPOSITES LIMITED (GB) | 2014-10-14 | — | — | US | claimed |
| US-8058329-B2 | as flameproofing agents for polymers such as polyesters, polyamides, polycarbonates, polystyrenes, polyethylene, polypropylene, phenolic and epoxy resins | Schill+Seilacher “Struktol” Aktiengesellschaft (DE) | 2011-11-15 | — | — | US | claimed |
| US-20110067812-A1 | CURE ACCELERATORS | HEXCEL COMPOSITES LIMITED (GB) | 2011-03-24 | — | — | US | claimed |
| EP-1866320-B1 | NITROGEN-CONTAINING BRIDGED DERIVATIVES OF 6H-DIBENZ(E,E)(1,2)-OXAPHOSPHORINE-6-OXIDES METHOD FOR PRODUCTION AND USE THEREOF AS FLAME-RETARDANT AGENTS | SCHILL & SEILACHER STRUKTOL AG (DE) | 2009-02-18 | — | — | EP | claimed |
| US-20080167405-A1 | Nitrous Bridged Derivatives of 6H-Dibenz[C,E][1,2]-Oxaphosphorine-6-Oxides, Process For the Preparation and Use Thereof | SCHILL+SEILACHER "STRUKTOL" AKTIENGESELLSCHAFT (DE) | 2008-07-10 | — | — | US | claimed |
| US-20050272883-A1 | Cure accelerators | HEXCEL COMPOSITES, LTD. (GB) | 2005-12-08 | — | — | US | claimed |
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| EP-0325762-B1 | Macrocyclic chelating agents and chelates thereof | BRACCO SPA (IT) | 1995-03-22 | — | — | EP | claimed |
| CN-120289335-A | Synthesis method of sulfonamide compound | 寿光诺盟化工有限公司 | 2025-07-11 | — | — | CN | disclosed |
| CN-114249979-B | Polyamide composition with NTC effect and preparation method thereof | 金发科技股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114106669-B | Curing agent based on N-hydroxyethyl benzene sulfonamide compound and preparation method and application thereof | 镇江牛盾新材料科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220193249-A1 | Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-O-) Units In A Ring | POLYTHERICS LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| CN-114249979-A | Polyamide composition with NTC effect and preparation method thereof | 金发科技股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | disclosed |
| US-5132409-A | Derivatives of 1,4,7,10-Tetraazacyclododecane | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1992-07-21 | — | — | US | disclosed |
| US-5095044-A | Odorless, discoloration inhibition | CIBA-GEIGY CORPORATION (US) | 1992-03-10 | — | — | US | disclosed |
| US-4950795-A | PRINTING PLATES, PAPER COATING | CIBA-GEIGY CORPORATION (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0325762-A1 | Macrocyclic chelating agents and chelates thereof | BRACCO S.p.A. (IT) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193249-A1 | Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-O-) Units In A Ring | BCR, CD2BP2, LANCL1 | SMN1; SMN2 3092/4885GLA 3280/4885NPC1 3200/4885 |
| US-20080167405-A1 | Nitrous Bridged Derivatives of 6H-Dibenz[C,E][1,2]-Oxaphosphorine-6-Oxides, Process For the Preparation and Use Thereof | PFAS, PCBP1, DNPH1 | SMN1; SMN2 1226/4885GLA 4462/4885NPC1 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.